New Delhi (Economy India): GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma India) on Monday reported a strong financial performance for the first quarter of FY2026-27, with its consolidated net profit rising 16% year-on-year to ₹237.18 crore for the quarter ended June 30, 2026.
The pharmaceutical major attributed the healthy performance to robust revenue growth, reflecting sustained demand across its portfolio and a solid start to the new financial year.
Net Profit Grows to ₹237 Crore
According to the company’s regulatory filing, consolidated net profit stood at ₹237.18 crore during the April-June quarter of FY27, compared with ₹205 crore reported in the corresponding quarter of the previous financial year.
The improvement in profitability highlights GSK Pharma India’s continued operational strength amid a competitive pharmaceutical market.
Revenue Surges Nearly 17%
GSK Pharma also reported a significant increase in revenue during the first quarter.
Consolidated revenue from operations rose to ₹938.44 crore, up from ₹805.17 crore in the same quarter last year, registering a year-on-year growth of nearly 16.5%.
The strong top-line performance indicates healthy sales momentum across the company’s pharmaceutical business.
Financial Highlights (Q1 FY27)
| Particulars | Q1 FY27 | Q1 FY26 | Growth |
|---|---|---|---|
| Net Profit | ₹237.18 crore | ₹205 crore | 16% |
| Revenue from Operations | ₹938.44 crore | ₹805.17 crore | 16.5% |
Positive Start to FY27
The first-quarter earnings provide a positive start to FY2026-27 for GSK Pharma India. The combination of higher revenue and improved profitability reflects the company’s ability to maintain growth while managing operational efficiencies.
India continues to be one of the fastest-growing pharmaceutical markets globally, supported by rising healthcare awareness, increasing demand for quality medicines, expanding healthcare infrastructure, and continued investments in research and innovation.
Industry Outlook
The Indian pharmaceutical sector is expected to remain resilient during FY27, driven by domestic demand, expanding healthcare access, and growing exports. Companies with diversified product portfolios and strong brand presence are likely to benefit from sustained market growth.
For GSK Pharma India, consistent financial performance will remain important as the company continues to strengthen its presence in key therapeutic segments while focusing on innovation and patient care.
(Economy India)
